MX2022010637A - Derivados de piridazina para modular el empalme de acidos nucleicos. - Google Patents

Derivados de piridazina para modular el empalme de acidos nucleicos.

Info

Publication number
MX2022010637A
MX2022010637A MX2022010637A MX2022010637A MX2022010637A MX 2022010637 A MX2022010637 A MX 2022010637A MX 2022010637 A MX2022010637 A MX 2022010637A MX 2022010637 A MX2022010637 A MX 2022010637A MX 2022010637 A MX2022010637 A MX 2022010637A
Authority
MX
Mexico
Prior art keywords
nucleic acid
dervatives
pyridazine
modulating nucleic
splicing
Prior art date
Application number
MX2022010637A
Other languages
English (en)
Inventor
Allen T Hopper
Peter Smith
Dominic Reynolds
Michael Walker Seiler
Anant A Agrawal
Frederic Vaillancourt
Original Assignee
Remix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Therapeutics Inc filed Critical Remix Therapeutics Inc
Publication of MX2022010637A publication Critical patent/MX2022010637A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Replacement Of Web Rolls (AREA)

Abstract

La presente descripción presenta compuestos y composiciones relacionadas que, entre otras cosas, modulan el corte y empalme de ácidos nucleicos, por ejemplo, el corte y empalme de un pre-ARNm, así como métodos de uso de los mismos.
MX2022010637A 2020-02-28 2021-02-28 Derivados de piridazina para modular el empalme de acidos nucleicos. MX2022010637A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062983537P 2020-02-28 2020-02-28
US202063007134P 2020-04-08 2020-04-08
US202063040474P 2020-06-17 2020-06-17
US202063072781P 2020-08-31 2020-08-31
US202063126491P 2020-12-16 2020-12-16
PCT/US2021/020173 WO2021174176A1 (en) 2020-02-28 2021-02-28 Pyridazine dervatives for modulating nucleic acid splicing

Publications (1)

Publication Number Publication Date
MX2022010637A true MX2022010637A (es) 2023-01-19

Family

ID=75278334

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022010637A MX2022010637A (es) 2020-02-28 2021-02-28 Derivados de piridazina para modular el empalme de acidos nucleicos.
MX2022010634A MX2022010634A (es) 2020-02-28 2021-02-28 Derivados de piridazina para modular el empalme de acidos nucleicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010634A MX2022010634A (es) 2020-02-28 2021-02-28 Derivados de piridazina para modular el empalme de acidos nucleicos.

Country Status (11)

Country Link
US (2) US20230140983A1 (es)
EP (2) EP4110774A1 (es)
JP (2) JP2023515618A (es)
KR (2) KR20220158236A (es)
CN (2) CN115551843A (es)
AU (3) AU2021228286A1 (es)
BR (2) BR112022017107A2 (es)
CA (2) CA3169667A1 (es)
IL (2) IL295954A (es)
MX (2) MX2022010637A (es)
WO (2) WO2021174176A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689863A1 (en) 2017-08-04 2020-08-05 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163405A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
EP4149937A1 (en) 2020-05-13 2023-03-22 CHDI Foundation, Inc. Htt modulators for treating huntington's disease
WO2023034836A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023081859A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Triazine amino derivatives for treating sca3
WO2023143605A1 (en) * 2022-01-31 2023-08-03 Novartis Ag Process for the synthesis of pyrazolyl derivatives useful as anti-cancer agents
WO2024042316A1 (en) * 2022-08-22 2024-02-29 Redx Pharma Plc. Pyrido-pyrazoles as inhibitors of ddr's for the treatment of fibrotic disorders and cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
EP3029035B1 (en) * 2013-07-31 2018-05-30 Sumitomo Chemical Company, Limited Tetrazolinone compound, and use thereof
JP6672296B2 (ja) * 2014-10-31 2020-03-25 ザ ジェネラル ホスピタル コーポレイション 強力なγ−セクレターゼモジュレータ
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
CA3065547A1 (en) * 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
EP3689863A1 (en) 2017-08-04 2020-08-05 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN111373057A (zh) 2017-09-25 2020-07-03 斯基霍克疗法公司 用于筛选和鉴定剪接调节剂的方法和组合物
AU2018351651B2 (en) * 2017-10-20 2023-01-05 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
AU2019216492A1 (en) * 2018-02-02 2020-08-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
KR20200142039A (ko) 2018-04-10 2020-12-21 스카이호크 테라퓨틱스, 인코포레이티드 암 치료용 화합물
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
JP2023515618A (ja) 2023-04-13
WO2021174176A9 (en) 2022-09-15
CA3169667A1 (en) 2021-09-02
JP2023515617A (ja) 2023-04-13
WO2021174176A1 (en) 2021-09-02
CN115551847A (zh) 2022-12-30
CN115551843A (zh) 2022-12-30
WO2021174170A9 (en) 2022-09-15
US20230365526A1 (en) 2023-11-16
BR112022017089A2 (pt) 2022-11-16
IL295954A (en) 2022-10-01
IL295953A (en) 2022-10-01
MX2022010634A (es) 2023-01-19
EP4110771A1 (en) 2023-01-04
EP4110774A1 (en) 2023-01-04
AU2021228288A1 (en) 2022-09-22
WO2021174170A1 (en) 2021-09-02
BR112022017107A2 (pt) 2022-11-16
KR20220158236A (ko) 2022-11-30
AU2024201568A1 (en) 2024-03-28
US20230140983A1 (en) 2023-05-11
CA3169643A1 (en) 2021-09-02
AU2021228286A1 (en) 2022-10-06
KR20220157407A (ko) 2022-11-29

Similar Documents

Publication Publication Date Title
MX2022010637A (es) Derivados de piridazina para modular el empalme de acidos nucleicos.
MX2022010683A (es) Compuestos y metodos para modular el empalme.
MX2022012677A (es) Compuestos y metodos para modular el empalme.
MX2022012678A (es) Compuestos y metodos para modular el corte y empalme.
MX2022010681A (es) Compuestos y metodos para modular el empalme.
MY201938A (en) Methods and compositions for modulating splicing
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020006072A (es) Métodos y composiciones relacionados con cpf1 para la edición genica.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2022003166A (es) Moduladores de il-17a y usos de los mismos.
WO2021046243A3 (en) Methods and compositions for genomic integration
MX2020007531A (es) Aminopirrolotriazinas como inhibidores de cinasa.
MX2020012765A (es) Métodos y compuestos de ácido nucleico modificado con lípidos.
UY38392A (es) Herbicidas de piridazinona e intermedios de piridazinona usados para preparar un herbicida
MX2021002617A (es) Indazol carboxamidas como inhibidores de cinasas.
MX2022000623A (es) Composiciones y kits para una suspension de omeprazol.
MX2023001558A (es) Composiciones para modular el corte y empalme.
MX2022015284A (es) Composiciones y metodos para la edicion del epigenoma.
CR20220483A (es) Compuestos y métodos para modular el empalme
MX2022014126A (es) Moduladores de enpp1 y usos de los mismos.
CU20220019A7 (es) Proteínas de fusión nkg2d
AU2020235128A8 (en) Transparent or semitransparent inverse microlatices of polyacrylamide as oil emulsion drift reducing agent
MX2020008884A (es) Composicion para eliminar compuestos que contienen azufre.
WO2020223273A3 (en) Compositions and methods for modulation of antibody activity